EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at
Experience Project.
Posted: Tue Jan 30, 2007 1:06 pm Post subject: T-0047
Tanabe Resumes MS Drug Study
Japanese pharmaceutical company Tanabe Seiyaku has resumed a phase II trial of its multiple sclerosis treatment after the FDA released its clinical hold on the study.
The drug, T-0047, was placed on clinical hold by the FDA in response to the reports that progressive multifocal leukoencephalopathy (PML), a rare nerve disorder, was associated with Tysabri. Tysabri is marketed by Biogen Idec and Elan Pharmaceuticals and is a monoclonal antibody with a similar receptor target to T-0047.
Tanabe and GlaxoSmtihKline have been waiting to resume the study of T-0047 after the FDA and the EU approved the marketing of Tysabri in 2006. Tysabri was approved with the condition that it must be administered at registered infusion centers.
The resumed clinical trial is being conducted in Europe, Canada, Australia and New Zealand.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum
We encourage you to also visit our Multiple Sclerosis story and support community on Experience Project.
Experience Project is a vast and powerful community where people connect anonymously through life experiences. It's made by the same people who built This is MS,
on the premise that no one life experience-- like having MS-- defines a person. It now covers over 2 million life stories. Find and share yours!
Forum FAQ
Search
Usergroups
Profile
Log in to check your private messages
Log in
